- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02844699
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mobilan is a nanoparticle-formulated, recombinant non-replicating adenovirus immunotherapeutic drug that directs expression of both toll-like receptor 5 (TLR5) and a specific agonistic ligand, entolimod (which is a recombinant form of the natural TLR5 ligand, flagellin).
The viral construct infects cells expressing the Coxsackie virus and adenovirus receptor (CAR), which has been shown in preclinical studies to be highly expressed in human prostatic tissue, including prostate cancer tissue. Upon infection, co-expression of both receptor and ligand in the same transfected cell triggers persistent autocrine stimulation of the nuclear factor-kappa B (NF-κB) signaling cascade. In a syngeneic mouse prostate cancer model, prostatic injection of Mobilan leads to activation of an innate immune response with infiltration of neutrophils and natural killer cells (NK) cells and induction of an adaptive immune response, comprising cytotoxic (cluster of differentiation [CD]8+) T cells. Necrotic changes in tumor cells were observed in Mobilan-treated animals with concomitant reductions in prostatic volume. Mobilan also show anti-metastatic activity in a surgical adjuvant mouse model of prostate cancer.
This clinical trial is a Phase Ib double-blinded, randomized, placebo-controlled trial evaluating the efficacy, safety, and pharmacology of either 1 or 2 injections of Mobilan or placebo when administered as neoadjuvant therapy directly into the prostates of patients with newly diagnosed prostate cancer.
All study subjects will receive 2 study drug injections administered 2 weeks apart and will be randomly allocated in a 1:1:1 ratio to 1 of the following 3 drug administration schedules:
- Arm A: Mobilan on both Day 1 and on Day 15.
- Arm B: Placebo on Day 1 and Mobilan on Day 15.
- Arm C: Placebo on both Day 1 and Day 15 Subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation
- Moscow State University of Medicine and Dentistry
-
Moscow, Russian Federation
- Moscow State Budgetary Healthcare Institution "City Clinical Hospital № 57" of Moscow Healthcare Department
-
Saint Petersburg, Russian Federation
- Federal State Budgetary Institution "Saint Petersburg Clinical Scientific and Practical Center for Special types of medical care (Oncological)"
-
Saint Petersburg, Russian Federation
- Federal State Budgetary Institution "Scientific Research Oncology Institute named after N.N. Petrov" of the Ministry of Health of the Russian Federation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subscribed Informed consent for participation in the trial
- Men aged 45 to 75 years
- Patients with histologically verified prostate cancer, stage Т1-Т3, N0, M0
- Patient's ECOG status 0-2
- Negative tests for serologic markers of HIV-infection, viral hepatitis В and С, syphilis
- Patient and his partner should agree to use barrier contraception throughout the study period
Exclusion Criteria:
- Failure to obtain Informed consent
- Clinical or radiological signs of metastases
- Indication to hormone therapy of prostate cancer
Clinically significant cardiovascular diseases:
- Myocardial infarction within 6 months prior the screening
- Unstable stenocardia within 3 months prior the screening
- Severe circulation failure (FC III)
- Clinically significant arrhythmias
- Hypotension (systolic blood pressure < 86 mm Hg) or bradycardia with HR < 50 beats per min.
- Uncontrolled arterial hypertension (systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg.)
- Clinically significant CNS diseases at the screening
- Current infection or another severe or systemic disease which increases risk of treatment sequel
- Pituitary gland or adrenal disorders in medical history
- Other malignant tumors within the last 5 years
- Other concomitant diseases in medical history which according to Investigator may aggravate during the study, including uncontrolled diabetes mellitus, rectal diseases, rectal fissures, hemorrhoid, rectal polyps, rectostenosis, inflammatory urinary diseases: chronic prostatitis, cystitis, urethral catheter, chronic urine retention.
- Complicated allergic history, systemic allergic reaction, any dietary allergy, intolerability, limitations or specific diets which according to the Investigator may be a contraindication for subject participation in the present study.
- Administration of drug products which have a marked effect on immune system within 3 previous months prior the screening, long-term intake of disaggregants (warfarin, low molecular heparin except for ThromboASS).
- Participation in other clinical studies or administration of investigational drug products within 30 days prior the screening, or persisting adverse reactions of any investigational drug product.
- Any clinically significant patient's health disorders and/or laboratory abnormalities not enlisted in the Protocol which are identified at the screening, and/or any reason which according to the Investigator may prevent the patient's participation in the study.
- Drug or alcohol abuse at the screening or in the past which according to the Investigator makes the patient ineligible for participation in the study.
- Vaccination made 14 days prior the study
- Unability to understand or follow study instructions
- Lack of availability during 6 months after administration of the investigational drug product, fails to follow visit schedule
19. Individual intolerability of the investigational drug product components
Study withdrawal criteria:
- Any patient may refuse from the study participation on his own wish in any moment on any study stage.
Principal Investigator may withdraw any patient from the study in the following cases:
- Investigator makes the decision that a patient should be withdrawn in his own best interests
- Patient develops any serious adverse reactions/events in the screening period
- Patient has been enrolled to the study with violations, or does not follow the protocol requirements
- Patient needs additional treatment in the screening period
- Sponsor has right to terminate the study in any moment.
- Regulatory authorities have right to terminate the study in any moment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mobilan (M-VM3) on both Day 1 and on Day 15
Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Investigational Drug Product (Mobilan (M-VM3)) administered 2 weeks apart.
All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
|
Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
|
Experimental: Placebo on Day 1 and Mobilan (M-VM3) on Day 15
Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) first on Day 1 and Investigational Drug Product (Mobilan (M-VM3)) in two weeks on Day 15.
All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
|
Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
5% infusion solution of dextrose (glucose)
Other Names:
|
Placebo Comparator: Placebo on both Day 1 and Day 15
Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart.
All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
|
5% infusion solution of dextrose (glucose)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and intensity of adverse events (according to CTCAE v 4.03 classification)
Time Frame: Baseline to up to 45 days after the first drug administration
|
Baseline to up to 45 days after the first drug administration
|
|
Counting of CD4+ and CD8+ cells in prostate biopsy and surgery samples
Time Frame: Baseline to up to 45 days after the first drug administration
|
Using immunological assays
|
Baseline to up to 45 days after the first drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in total Prostate-specific antigen (PSA) level
Time Frame: Baseline to up to 45 days after the first drug administration
|
Baseline to up to 45 days after the first drug administration
|
|
Value of the Irani score of post-operative prostate tissue (if material is available for analysis)
Time Frame: On Day 30 after the first drug administration
|
Irani J (1997) scale include histological assessment of slide mounts obtained after operation as follow: Degree of immune cell infiltration: 0 - No inflammatory cells, 1 - Scattered inflammatory cell infiltrate within the stroma without lymphoid nodules, 2 - Nonconfluent lymphoid nodules, 3 - Large inflammatory areas with confluence of infiltrate |
On Day 30 after the first drug administration
|
Value of the Gleason score of post-operative prostate tissue (if material is available for analysis)
Time Frame: On Day 30 after the first drug administration
|
The Gleason grading system is used to evaluate the stage of prostate cancer using samples from biopsy or post- surgical samples as follow: 1 - The cancerous prostate closely resembles normal prostate tissue. 2 - The tissue still has well-formed glands, but they are larger and have more tissue between them. 3 - The tissue still has recognizable glands, but the cells are darker. 4 - The tissue has few recognizable glands. 5 - The tissue does not have any or only a few recognizable glands. |
On Day 30 after the first drug administration
|
Plasma concentration of inflammatory cytokines
Time Frame: Baseline to up to 45 days after the first drug administration
|
Baseline to up to 45 days after the first drug administration
|
|
Presence of protein 502s in blood plasma
Time Frame: Baseline to up to 45 days after the first drug administration
|
Using ELISA assay
|
Baseline to up to 45 days after the first drug administration
|
Presence of protein 502s in prostate biopsy and surgery samples
Time Frame: Baseline to up to 45 days after the first drug administration
|
Using ELISA assay
|
Baseline to up to 45 days after the first drug administration
|
Presence of protein TLR5 in prostate biopsy and surgery samples
Time Frame: Baseline to up to 45 days after the first drug administration
|
Using ELISA assay
|
Baseline to up to 45 days after the first drug administration
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PNC-M-VM3-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Mobilan (M-VM3)
-
Panacela Labs LLCCompleted
-
HighField Biopharmaceuticals CorporationRecruiting
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | VaricellaFrance, Italy
-
Fundació Institut de Recerca de l'Hospital de la...Sheba Medical Center; iMinds; Semmelweis University; AQuAS, Agència de Qualitat...CompletedSchizophreniaSpain, Hungary, Israel
-
Samueli Institute for Information BiologyWilliam Beaumont Army Medical Center; Palmer Center for Chiropractic Research... and other collaboratorsUnknown
-
Kreiskrankenhaus DormagenCompletedFeasibility of Measurement of a Neuromuscular Block at the m. TrapeziusGermany
-
CicloMed LLCCmed Clinical ServicesCompletedAdvanced Solid TumorsUnited States
-
Tulane UniversityRecruitingDepression | AnxietyUnited States
-
University of the Incarnate Word59th Medical Wing; United States Naval Medical Center, San Diego; Madigan Army... and other collaboratorsCompletedPreterm Birth | Maternal | Infant, Low Birth Weight | Anxiety Fear | Prenatal DepressionUnited States
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLCCompletedHIV Infections | MeaslesUnited States, Puerto Rico